ArticleJournal of feline medicine and surgery2025
Hypersomatotropism in diabetic cats in Australia.
Article in Journal of feline medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesHypersomatotropisim is an excessive production of growth hormone from the anterior pituitary gland, typically secondary to a pituitary tumour, which causes insulin-resistant diabetes and the clinical syndrome of acromegaly. Studies have shown the prevalence of hypersomatotropism among diabetic cats in the UK, Switzerland and the Netherlands to be in the range of 17.8-26%. The prevalence of hypersomatotropism in Australia is not known. Our objective was to determine the prevalence of hypersomatotropism in diabetic cats in Australia.MethodsResidual serum samples from cats with increased fructosamine or increased blood glucose and a clinical history of diabetes were submitted for the measurement of insulin-like growth factor 1 (IGF-1). Hypersomatotropism was defined as an IGF-1 of 1000 ng/ml or more. The prevalence and associated confidence interval were calculated (Jeffrey's method). Clinicopathological features between diabetic cats with and without hypersomatotropism were compared.ResultsSerum samples from 87 cats were included in the final analysis. IGF-1 was above 1000 ng/ml in 14 cats. The absolute prevalence of IGF-1 was 16%; therefore, the prevalence of hypersomatotropism (IGF-1 levels >1000 ng/ml) in an Australian population is estimated to be in the range of 9.5-24.9%. No significant difference was detected between breed (pedigree vs domestic), sex, age nor location (metropolitan vs regional) in cats with and without hypersomatotropism. Glucose and fructosamine concentrations did not differ between cats with and without hypersomatropism (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.